L. Rodrigues

359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

R. Govindan, A. Chiang, R. Salgia, 2020 .

OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC

R. Govindan, A. Chiang, R. Salgia, 2021 .